NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00. In the quarter to March 2025, EPS grew 232.0% and free cash flow grew 28.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow NKGN
NKGen Biotech, Inc. (NKGN) Dividend Safety Score
NKGen Biotech, Inc.'s Dividend Safety Score for fiscal 2022 cannot be worked out: does not pay a regular dividend.
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How fiscal 2022’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings earnings at or below zero | — | — | Fail | 0 |
| Payout of free cash flow free cash flow at or below zero | — | — | Fail | 0 |
| Net debt / EBITDA EBITDA at or below zero | — | — | Fail | 0 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 1 fiscal years | 2 | — | Fail | 4 |
| Dividend Safety Score | n/a — does not pay a regular dividend | — | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| BOLT Bolt Biotherapeutics, Inc. compare | — |
| MTVA MetaVia Inc. compare | — |
| IMRN IMMURON compare | — |
| SNTI Senti Biosciences, Inc. compare | — |
| CSCIF COSCIENS Biopharma Inc. compare | — |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | — |
| ADIL Adial Pharmaceuticals, Inc. compare | — |
| JAGX Jaguar Animal Health, Inc. compare | — |
| NKGN NKGen Biotech, Inc. | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings